Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

NYZOL 300 MG COMPRIMIDOS - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/NYZOL 300 MG COMPRIMIDOS

Approved

STANDARD

NYZOL 300 MG COMPRIMIDOS

Neuraxpharm Spain S.L.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Jun 20, 2022
Approval ID: 4493bc5ffd2e7688
Company: Neuraxpharm Spain S.L.
Type: Standard

Approval Details

Approval Id: 4493bc5ffd2e7688
Drug Cima Aemps Name: NYZOL 300 MG COMPRIMIDOS
Register Number: 87869
Holder Company Name: Neuraxpharm Spain S.L.
Marketing Company Name: Neuraxpharm Spain S.L.
Authorization Date: 2022-06-20
Dosage Form: COMPRIMIDO
Dose: 300 mg
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: Yes
Company Name: Neuraxpharm Spain S.L.

Active Ingredients

ZONISAMIDA

300 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Jun 20, 2022

Approval ID

4493bc5ffd2e7688

Type

Standard

Back to CIMA-AEMPS Approvals